Journal of Education, Health and Sport
May 7, 2026
Kinga Zachar, M. Sito, Filip Jurkowski et al.
Psilocybin-assisted therapy can produce rapid reductions in depressive symptoms, often within days, in carefully selected patients treated in controlled settings. Short-term benefits have been reported in both major depressive disorder and treatment-resistant depression, although findings in treatment-resistant depression are less consistent. In a head-to-head trial, psilocybin was not superior to escitalopram on the primary endpoint, while several secondary outcomes favored psilocybin. Follow-up studies suggest benefits may persist for weeks to months, but longer-term evidence remains limited and heterogeneous. Under supervision, psilocybin was generally well tolerated, with mostly transient adverse effects including anxiety, nausea, headache, dizziness, and brief cardiovascular activation.
Journal of Education, Health and Sport
March 7, 2025
Michał Orzechowski, Joanna Orzechowska, Paulina Fijałek et al.
As depression rates rise globally, psilocybin shows promise as a treatment for treatment-resistant depression, but its safe clinical use requires clear safety parameters. This paper reviews risks associated with psilocybin therapy, drawing on a literature search of PubMed and Google Scholar for studies on challenges and risks in treating treatment-resistant depression. It aims to help understand these risks as a basis for safety-focused treatment protocols.
Journal of Education, Health and Sport
August 15, 2023
Justyna Woźniak, Rafał Bogacz, Magdalena Gaik et al.
Psilocybin, a classic psychedelic found in magic mushrooms, has been used for centuries in religious ceremonies and is now being studied for treating psychiatric disorders. Recent research suggests psilocybin may effectively treat cancer-related psychiatric distress, treatment-resistant depression, and addiction, with some reports indicating usefulness for obsessive-compulsive disorder and cluster headaches. Psychological support during treatment is crucial. More large-scale, randomized, placebo-controlled studies are needed to confirm these promising findings.
Journal of Education, Health and Sport
June 7, 2023
Paulina Czuchryta, Rafał Babiak, Karolina Bajak et al.
Major depressive disorder (MDD) may soon become the most common disease after cardiovascular diseases and cancer. Its development involves genetic factors, inflammation, hormonal disorders, brain structure changes, and neurotransmission disruptions. The microbiome-gut-brain axis influences mood regulation; bacteria such as Escherichia, Shigella, and Enterococcus may negatively affect MDD development and treatment response, while probiotics like Lactobacillus helveticus R0052, Bifidobacterium longum, and Clostridium butyricum MIYAIRI 588 may help reduce symptoms. The FDA has approved intranasal esketamine for treatment-resistant depression and MDD with severe suicidal thoughts, offering rapid symptom reduction. Further research on microbiota's role is needed.